SecBot SecBot
144 ·Filed Nov 9, 2026

BIO

BIO-RAD LABORATORIES, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 9h ago SEC0001950047-26-010897
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider intent-to-sell filing with immaterial size. Monitor for any subsequent Form 4 filings to confirm execution, but no further action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$386.48
T+0 close · Nov 9, 2026 · via day close
Latest settled
−0.12%
T+1 · $386.00 · next T+5 in 4h
Vs SPY
−1.44%
α at T+1
Latest observation
−4.75%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $386.48entry
  2. T+1 · 6d ago −0.12%α −1.44% · $386.00
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jonathan P. DiVincenzo, an officer of Bio-Rad Laboratories, filed a Form 144 notice of intent to sell 919 shares of common stock, with an approximate market value of $359,000 based on the filing. The shares were acquired as restricted stock on October 24, 2025, and the proposed sale is scheduled for November 9, 2026. The sale represents a small fraction of the company's $9.9B market cap and is likely a routine diversification trade by an officer.

Key Facts

  • Jonathan P. DiVincenzo, an officer of Bio-Rad, filed Form 144 to sell 919 shares of common stock.
  • The approximate market value of the proposed sale is $358,842 (based on 919 shares at the filing reference price of ~$390.47 per share).
  • Shares were acquired as restricted stock on October 24, 2025, via an issuer transaction.
  • The proposed sale date is November 9, 2026.
  • The sale represents about 0.0036% of Bio-Rad's $9.9B market cap, a de minimis amount.

Financial Impact

919 shares, approximately $359,000 in value, negligible relative to $9.9B market cap

dilution

Risk Factors

  • Form 144 is only an intent to sell; the sale may not occur.
  • No additional context on the insider's total holdings is provided, so the proportional impact on his position is unknown.

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
50% bullish (10 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010897
Document: 0001950047-26-010897-index.html0001950047-26-010897
Document: 0001950047-26-010897.txt0001950047-26-010897

US Market Status

Market Closed · Opens in 6h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026